Chunghwa Chemical Synthesis & Biotech Balance Sheet Health
Financial Health criteria checks 5/6
Chunghwa Chemical Synthesis & Biotech has a total shareholder equity of NT$3.4B and total debt of NT$1.2B, which brings its debt-to-equity ratio to 35.8%. Its total assets and total liabilities are NT$5.2B and NT$1.8B respectively. Chunghwa Chemical Synthesis & Biotech's EBIT is NT$280.8M making its interest coverage ratio 26.2. It has cash and short-term investments of NT$269.6M.
Key information
35.8%
Debt to equity ratio
NT$1.20b
Debt
Interest coverage ratio | 26.2x |
Cash | NT$269.57m |
Equity | NT$3.35b |
Total liabilities | NT$1.82b |
Total assets | NT$5.17b |
Recent financial health updates
No updates
Recent updates
Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 04A Look At The Intrinsic Value Of Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)
Apr 01Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TPE:1762) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Mar 04What To Know Before Buying Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762) For Its Dividend
Jan 28Should You Rely On Chunghwa Chemical Synthesis & Biotech's (TPE:1762) Earnings Growth?
Jan 02The Chunghwa Chemical Synthesis & Biotech (TPE:1762) Share Price Is Up 131% And Shareholders Are Boasting About It
Dec 06Financial Position Analysis
Short Term Liabilities: 1762's short term assets (NT$1.8B) exceed its short term liabilities (NT$831.4M).
Long Term Liabilities: 1762's short term assets (NT$1.8B) exceed its long term liabilities (NT$990.0M).
Debt to Equity History and Analysis
Debt Level: 1762's net debt to equity ratio (27.8%) is considered satisfactory.
Reducing Debt: 1762's debt to equity ratio has reduced from 40.2% to 35.8% over the past 5 years.
Debt Coverage: 1762's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 1762's interest payments on its debt are well covered by EBIT (26.2x coverage).